US Pharma MarketingNeurocrine cites work disruption data to make case for timely movement disorder diagnosis
Neurocrine Biosciences has shared survey data showing how tardive dyskinesia affects the ability of patients and caregivers to work, supporting the company’s case for timely treatment of the movement disorder.
Neurocrine Biosciences has shared survey data showing how tardive dyskinesia affects the ability of patients and caregivers to work, supporting the company’s case for timely treatment of the movement disorder.
Source: FiercePharma